Compare GFAI & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | APVO |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 21.7M |
| IPO Year | N/A | N/A |
| Metric | GFAI | APVO |
|---|---|---|
| Price | $0.76 | $1.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | 397.9K | ★ 1.1M |
| Earning Date | 09-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,987,715.00 | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.38 | N/A |
| 52 Week Low | $0.58 | $1.00 |
| 52 Week High | $3.88 | $109.80 |
| Indicator | GFAI | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.28 | 40.36 |
| Support Level | $0.75 | $1.00 |
| Resistance Level | $0.80 | $1.11 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 10.93 | 24.39 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.